




Immunization Branch

Immunization Updates for Providers

Friday, November 1, 2024

9:00 am – 10:30 am

Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



Housekeeping

Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#).



To be added to the CDPH email messaging listserv for providers, please email your request to blanca.corona@cdph.ca.gov.



If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov.

Agenda: Friday, November 1, 2024

No.	Topic	Presenters (CDPH)	Time (AM)
1	Welcome and Announcements	Leslie Amani	9:00 – 9:05
2	A Special Announcement	Robert Schechter, MD	9:05 – 9:10
3	COVID-19 Vaccine Administration Data	Josh Quint	9:10 – 9:15
4	CA Immunization Registry	Michael Powell	9:15 – 9:20
5	Vaccines for Children (VFC)	Christina Sapad	9:20 – 9:25
6	Mpox	Louise McNitt, MD	9:25 – 9:30
7	Clinical	Floria Chi, MD	9:30 – 9:50
8	CA Bridge Access Program	Maria Volk	9:50 – 9:55
9	Vaccine Pharmacy Update	Edward Salaguinto, PharmD, RPh	9:55 – 10:00
10	Vaccine Management (My Turn / myCAvax)	Josh Pocus and Maria Volk	10:00 – 10:15
11	Resources and Q&A	Leslie Amani and CDPH SMEs	10:15 – 10:30

Announcements

Leslie Amani, CDPH



**OLDER ADULTS NEED
VACCINE PROTECTION FROM
FLU, RSV & COVID-19.**





Webinar: Virtual Grand Rounds



Virtual Grand Rounds

EMERGING PUBLIC HEALTH ISSUES

Join our Virtual Grand Rounds: From Avian Flu to COVID-19 – How the “One Health” Approach Improves Human, Animal and Environmental Health on Tuesday, November 12, 2024, from 12:00 to 1:00 p.m. PT.

While traditional medical education has focused only on the human patient, over time we have recognized the profound influence that environmental and animal have on human health. By looking at the whole picture rather than individual pieces, an approach called “One Health,” we can be more effective not only at preventing human disease, but also at creating a sustainable planet for all life.

In this Virtual Grand Rounds, our guests will discuss examples of “One Health” challenges and describe how bringing this mindset into our clinics, societal actions and policy is vital as we face challenges from COVID-19 to avian influenza.



Erica Pan, M.D., MPH, California State Epidemiologist and Deputy Director, California Department of Public Health, Center of Infectious Diseases



Kim Conway, DVM, MPVM, DACVPM, One Health Lead, California Department of Public Health, Center for Environmental Health



CALIFORNIA
MEDICAL
ASSOCIATION

When: Tuesday, November 12, 2024

Time: 12:00 pm – 1:00 pm, PT

Registration link here:
[CMA Virtual Grand Rounds](#)

EZIZ: Parents Top Questions About Immunizations



ENHANCED BY Google

A one-stop shop for immunization training and resources.

Home

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

Contact VFC

Phone: (877) 243-8832

Hours:

Mon-Thurs, 9AM-4:30PM

Friday, 9AM-4PM

Send us an email

Fax: (877) 329-9832

► VFC Field Representatives

► Find VFC providers

► Sign up for EZIZ emails

► Frequently Asked Questions

Answers to Parents' Top Questions



As a parent, you want to make the best decisions to protect your child—staying informed will help. Your questions are important, and you deserve reliable information to support your decisions. If you want to learn more, ask your doctor for a “consultation visit,” or check out the websites at the end.

1. What kind of side effects should I know about?

Any medicine can cause reactions in some people. The most common side effects from vaccines are swelling or tenderness at the injection site and fever. Serious allergic reactions are very rare, happening in about 1 person out of a million¹ shots given and similarly quite rare for COVID-19 vaccinations. If you are concerned about possible side effects, ask questions about what to expect. If you notice an unusual reaction hours or days after your child's immunizations, call the doctor's office for advice.

2. Why do children today get so many immunizations?

Thirty-five years ago, vaccines protected young children from only seven diseases. Today, we can protect them from at least 15 dangerous diseases because of medical advances. Many shots are also “boosters” of the same vaccine to give children the best protection possible.

3. Are Vaccines safe?

Yes. Vaccines are very safe². In fact, experts including the American Academy of Pediatrics, the National Academy of Medicine, and the World Health Organization agree that vaccines are safe. Millions of children and adults are vaccinated every year—safely. Thousands of people take part in clinical trials to test a vaccine before it is licensed by the Food and Drug Administration (FDA). After it's licensed, the Vaccine Adverse Events Reporting System (VAERS) helps track any health effect that happens hours, days, weeks, or even months later. Anyone can report a possible side effect so that it can be studied. VAERS and other monitoring programs help ensure vaccines are safe.

4. Are diseases of the “old days” still around?

7. What about “natural immunity”?

Some people think getting a disease is the “natural” way to trigger the body's immune response, but this comes at a risk—many vaccine-preventable diseases can have dangerous complications, like pneumonia, blindness, brain damage, and even death.

Vaccines safely trigger a [natural immune response](#)—but do not cause the disease. While vaccines can prevent mild and severe illnesses, some, such as flu and COVID-19 vaccines, are more effective in preventing hospitalization and death than milder disease.

8. Is it safe for a child's immune system to have multiple shots?

Yes. Children are exposed to [hundreds of viruses and bacteria](#)⁵ during normal activities like eating and playing. Getting vaccines is no extra burden on the immune system—even for babies.⁶ Getting combination vaccines, like MMR (that protects against measles, mumps, and rubella), or [getting multiple shots during one visit is very safe](#). Today's vaccines are more refined, so even though kids receive more vaccines, they receive [far fewer antigens overall](#)⁷ (compared to their parents or grand- parents).

9. What about kids with allergies or other health conditions

Vaccines are safe for kids with [most kinds of allergies](#).⁸ Getting shots may be especially important for children with certain health problems who can get very sick if they catch a disease. If your child has an allergy or any health condition, talk with your doctor. The doctor can tell you if any vaccine should be postponed or avoided. There is [no link](#) between developing asthma or allergies and vaccines.

10. What about autism?

[Resource: Parents Top Questions About Immunizations](#)

CDPH Office of Communications Toolkits

CDPH Communication Toolkits



CDPH California Department of Public Health

Q

I am looking for I am a Programs A-Z Index

Home | Programs | Office of Communications | Infectious Diseases Toolkits

OFFICE OF COMMUNICATIONS

Communications Toolkits

- Infectious Diseases
 - Bird Flu
 - Flu & COVID-19
 - Let's Talk Mpox
 - Lyme Disease
 - Measles
- Behavioral Health
- Health & Safety
- Emergency & Weather
- A-Z Index
 - Mpox
 - Norovirus
 - Respiratory Virus Prevention
 - Routine Immunizations
 - RSV
 - Sexual Health
 - Valley Fever
 - West Nile Virus

Disclaimer
Local health jurisdictions (LHJs) and community-based organizations (CBOs) may co-brand materials created by the CDPH Office of Communications Toolkits by adding their agency logo next to or near the CDPH logo. Materials may not be altered or edited in any other way, without the written consent of the CDPH logo.

Bird Flu

Routine Immunizations

CDPH Office of Communications Toolkits

TIPS FOR STAYING HEALTHY THIS VIRUS SEASON

Reduce your risk of catching and spreading respiratory viruses like flu, COVID-19 and RSV

Stay Up to Date on Vaccines

Vaccines are the best protection against severe illness. Visit [MyTum.ca.gov](https://mytum.ca.gov) to schedule your vaccines or contact your health care provider.

- [Flu and COVID-19 vaccines](#) are recommended for everyone 6 months and older.
- [RSV immunizations](#) are recommended for eligible pregnant people, older adults, infants and toddlers.

Stay Home if You're Sick

Stay home and away from others if you have any symptoms of [flu](#), [COVID-19](#) or [RSV](#).

Test and Treat

Test for COVID-19 and flu if you know you've been exposed or have symptoms. You may be eligible for [prescription COVID-19 treatments](#) or flu treatment. Talk to your doctor.

Consider Wearing a Mask

Consider wearing a high-quality mask in crowded or indoor areas, especially if you're sick.

Wash Your Hands

Wash your hands often with soap and warm water for at least 20 seconds. If soap and water are not available, use a hand sanitizer with at least 60% alcohol.

Cover Your Cough or Sneeze

Cough or sneeze into your elbow, arm or a disposable tissue. Make sure to wash your hands or sanitize and dispose of your tissue after.

Ventilate Indoor Spaces

Open doors and windows as much as possible to bring in fresh outdoor air. This helps keep virus particles from building up indoors.



September 2024 • © 2024, California Department of Public Health



Protect Yourself from Respiratory Viruses

Older adults, especially those with weakened immune systems, are at greater risk for getting very sick from respiratory viruses. Take these steps to lower your risk.

Stay Up to Date on Vaccines

As we get older, we need updated vaccines to keep our immune systems healthy and strong. Vaccines are our best protection against severe illness, hospitalization, and death from [flu](#), [COVID-19](#), and [RSV](#).

Talk to your health care provider to make sure you're **up to date on all your vaccines!**

Get COVID-19 and Flu Treatments

If you have symptoms, contact your health care provider to get tested (or take an at-home COVID-19 test). If you test positive, ask your health care provider about prescription treatments to prevent symptoms from getting serious. **Act fast, most of these medications must be taken within the first 5 days** of symptoms.

Consider Extra Precautions to Prevent Spread

- Wear a mask in crowded indoor spaces
- Increase ventilation by opening windows and doors
- Stay away from others if you're sick
- Wash your hands often
- Cover your cough or sneeze




Need more info? go.cdph.ca.gov/respiratory-viruses

September 2024 • © 2024, California Department of Public Health

Respiratory Virus Season Toolkit

CDPH Office of Communications

Sign Up for the CDPH Communications Tools & Information Newsletter



Communication Tools & Information
California Department of Public Health

Sign up to receive weekly email updates from the California Department of Public Health. Get the latest public health guidance and communications tools & resources for advancing public health in California and beyond.

First Name*

Last Name*

E-mail*

Organization

Sign up to receive the
[CDPH Office of Communications Tools & Information Newsletter](#)

Webinar Calendar: November 2024

November is Native American Heritage Month

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
November is National Long-term Care Awareness Month					1 Provider Webinar	2
3 Daylight Saving Time	4	5	6	7	8	9
10 World Immunization Day	11 Veteran's Day	12	13	14	15 Provider Webinar	16
17	18	19	20	21	22	23
24	25 Thank you! 	26	27	28 Thanksgiving Day	29 No Provider Webinar	30

A Special Announcement

Robert Schechter, MD, CDPH

Thank you, California Providers!



2020

2021

2022

2023

2024

The first COVID-19 vaccine was administered in California on December 14, 2020.



California COVID-19 vaccine doses administered in California as of October 25, 2024, reached

100 Million!



COVID-19 Vaccine Administration Data

Josh Quint, CDPH




COVID-19 Vaccine Administration Summary

as of October 28, 2024

100,089,805


Total Doses Administered:

Daily Doses Administered: **Statewide**



3,287,975

2024-2025 COVID-19 Recipients




Trends in COVID-19 Vaccine Administration


as of October 28, 2024

CDC recommends the 2024-25 COVID-19 vaccine for everyone 6 months and older

An updated vaccine protects against:

- COVID-19 variants spreading now
- Severe illness, hospitalization, and death






bit.ly/mm7337e2
SEPTEMBER 10, 2024



[CDC- 2024-2025 COVID-19 Vaccine Recommendation](#)

[CDC- Staying Up to Date](#)

Doses Administered by Age Group, Past 4 Weeks




COVID-19 Vaccine Uptake Comparison

as of October 28, 2024

Current COVID-19 vaccine uptake keeping pace with last year (-0.6% pts lower)

Current vs Last Year's COVID-19 Vaccine Dose Uptake by % of Population in 66 days since EUA




EUA = Emergency Use Authorization

COVID-19 Vaccine Uptake Comparison by HPI

as of October 28, 2024

- Highest uptake in the HPI Q4 population
- Overall, rates comparable to last season
 - Largest difference amongst HPI Q4 (-1.9%)
 - Faster uptake this season in HPI Q1 (+0.2%)

Current vs Prior Season COVID-19 Doses % of Population in 66 days since EUA



EUA = emergency use authorization

HPI Q4 = Communities with most healthy conditions (least disadvantaged)


HPI Q1 = Communities with least health conditions (most disadvantaged)

Provider Type of COVID-19 Vaccinations by Race

as of October 28, 2024

- Statewide, more than **50%** of doses are administered by **pharmacies**
- Provider type varies across race/ethnicity groups
 - **Black and NHPI populations** more likely to receive vaccine from healthcare providers
 - **AIAN populations** have higher rate of vaccination at Public Health


Updated 2024-2025 Doses by Provider Type and Race/Ethnicity



AIAN = American Indian or Alaska Native
NHPI = Native Hawaiian or Pacific Islander
Data for detailed Asian and NHPI categories not currently available

COVID-19 Vaccination At-a-Glance

as of October 28, 2024



[Public Dashboard Link](#)

System Notes

- Up-to-Date status defined as at least one dose of the updated 2024 – 2025 COVID-19 vaccine
- 2024 – 2025 COVID-19 vaccine data not yet available on public facing website (release date TBD)
- Email cdphvaccinedatateam@cdph.ca.gov with questions and comments.

[Public Dashboard Link](#)

California Immunization Registry

Michael Powell, CDPH

CAIR2 Release Roadmap

Past Release

September 18, 2024 (2.8.18)

Sprint 16

User Interface

- ✓ Add Vivotif manufacturer to dropdown on Manage NDC
- ✓ Add RabAvert manufacturer Bavarian Nordic to dropdown on Manage NDC screen
- ✓ Trivalent Flu Vaccines Codes for 2024/2025
- ✓ Quadrivalent Flu Vaccines Codes for 2024/2025

Data Exchange

- ✓ Source of Immunization for Historical Doses
- ✓ Add PCV21
- ✓ Trivalent Flu Vaccines Codes for 2024/2025
- ✓ Quadrivalent Flu Vaccines Codes for 2024/2025
- ✓ New code sets for Havrix, Pfizer Comirnaty & Abrysvo

Technical

- ✓ Merge parsing research & cleanup
- ✓ Update pending immunization cron job

Current

November 3, 2024 (2.8.19)

Sprint 17

User Interface

- ✓ PPSV23 bug in children under 5 yo
- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90
- ✓ Remove Flucelvax NDC from ONB & TRN

Data Exchange

- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90
- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version
- ✓ A dose amount of '1.0' is returned in RXA-6 for all VXP messages
- ✓ ACK fixes
- ✓ Allow "Md" to the name fields
- ✓ Remove Flucelvax NDC from ONB & TRN

Technical

- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version

Future Release

Targeted- November 20, 2024 (2.8.20)

Sprint 18

User Interface

- ✓ Add New vaccine Vaxchora
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown
- ✓ 2024-2025 COVID Seasonal Schedule
- ✓ Update NOS vaccines to carry "unspecified" trade names

Data Exchange

- ✓ Add New vaccine Vaxchora
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown
- ✓ 2024-2025 COVID Seasonal Schedule
- ✓ Update NOS vaccines to carry "unspecified" trade names
- ✓ Collect SOGISC Data (Research)

Merge

- ✓ Sub race code issue on pending clients

My DVR Release Roadmap

Past Release

October 1, 2024 (UR75)

Unified Release 75

DVR Front End

- ✓ Renew frontend certificate for generating COVID-19 QR codes and California Immunization Records on mobile devices
- ✓ Enhance COVID-19 Vaccine Record retrieval process for unsupported CVX codes
- ✓ Update inactive Call Center number to CAIR Help Desk for My DVR home page footer

DVR Integration

- ✓ Increase fault tolerance on Databricks API calls
- ✓ Cleanup historical files for delta tables
- ✓ Role Based Access Control Databricks cleanup

Staff Remediation Tool (SRT)

- ✓ Optimize backed processes for VAT image deletion and SMS Returns utilizing Azure Functions
- ✓ Update inactive Call Center number to CAIR Help Desk for all SMS communications to users

Virtual Assistant Tool (VAT)

- ✓ Ensure formatting consistency throughout VAT

Current

October 29, 2024 (UR76)

Unified Release 76

DVR Front End

- ✓ Enhance DVR Navigation Bar to provide better user experience for residents
- ✓ Eliminate recipient's name from AWS Lambda requests and logs to limit non-essential user data transmission

DVR Integration

- ✓ Removal of outdated Iceberg data from prior consolidation efforts that are no longer needed
- ✓ Update Stage environment to truncate tables in Databricks

Staff Remediation Tool (SRT)

- ✓ Cleanup of obsolete backend components following Auto-Remediation optimization

Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring

Future

(UR77+ until EOY)

Upcoming Unified Releases

DVR Front End

- ✓ Release Google Wallet integration for android users to save CA Immunization Record to mobile devices
- ✓ FAQ page search feature to enable fuzzy matching across all pages
- ✓ Evaluator Series and Booster dose logic enhancements to the CA Immunization Record
- ✓ Update to latest CDPH logo and branding

DVR Integration

- ✓ Optimize backend Databricks API calls and enhance alerts for merged records
- ✓ Repoint views in DVR pipelines

Staff Remediation Tool (SRT)

- ✓ Enhance User Management page to add/inactive users
- ✓ Ticket History enhancement to display all changes made to a ticket
- ✓ Consolidate CVX codes to backend mapping table that will capture any new CVX code

Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring

Contact Information



- CAIR Contact Information
 - General Information
 - [California Immunization Registry](#)
 - Help Desk
 - CAIRHelpDesk@cdph.ca.gov
 - 800-578-7889
 - Data Exchange
 - CAIRDataExchange@cdph.ca.gov
 - My DVR
 - [Digital Vaccine Record \(ca.gov\)](#)
 - [DVR Virtual Assistant](#)



Vaccines for Children (VFC)

Christina Sapad, CDPH

VFC Respiratory Immunization Orders

- **Reminder:** “Order all ACIP-recommended vaccines (including flu and special-order vaccines) to meet the needs of the total VFC-eligible patient populations reported for the VFC PIN.”
(*VFC Program Provider Agreement Addendum #8A*)
- **Flu**
 - 539 providers have not ordered flu vaccine yet this season
 - Targeted communication sent last week
- **COVID-19**
 - Over 140,000 doses of COVID-19 vaccine have been ordered, but many providers have still not submitted a request for COVID-19 vaccines
 - Continue to order COVID-19 vaccines as needed!
- **RSV**
 - Open ordering available for all VFC providers
 - Continue to order RSV immunizations as needed!



MPOX Ordering in the VFC Program

- JYNNEOS vaccine has been added to the CDC Pediatric Contracts and will be made available on the VFC order form on myCAvax very soon!
 - 10-pack of single-dose vials
- JYNNEOS through VFC will only be for eligible children aged 18 years and older who meet the specified criteria outlined in the VFC Resolutions. [ACIP Vaccines for Children Program Vaccines to Prevent MPOX \(cdc.gov\)](#).
 - JYNNEOS vaccine is recommended for children aged 18 years of age at increased risk of MPOX

Mpox

Louise McNitt, CDPH

VFC Resolution for JYNNEOS

- JYNNEOS vaccine is recommended for children aged 18 years of age at increased risk of mpox, including:
 - Persons who are gay, bisexual and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had:
 - At least 1 sexually transmitted disease
 - More than 1 sex partner
 - Sex at a commercial sex venue
 - Sex in association with a large public event in a geographic area where mpox transmission is occurring
 - Persons who are sexual contacts of the persons described above
 - Persons who anticipate experiencing any of the situations described above

Breaking News for JYNNEOS Vaccine

- Extension of expiration date for JYNNEOS vaccine that was provided from Strategic National Stockpile (SNS)
 - Lot #s
 - FDP00017
 - FDP00018
 - FDP00019
 - FDP00020
 - Original expiration date: October 31, 2024
 - New expiration date: August 31, 2026
- Does NOT apply to vaccine that has been stored at refrigerated temperatures (2°C - 8°C or 36°F - 46°F)
- Does not apply to commercial vaccine
- More information:
 - [October 2024 Dear Healthcare Provider Letter - Extension of expiration dates for JYNNEOS \(Smallpox and Monkeypox Vaccine, Live, Non-replicating\)](#)
 - [October 18, 2024 Approval Letter - JYNNEOS](#)

Commercial JYNNEOS Product

- How Supplied
 - Package of 10 single-dose vials
 - Package of 20 single-dose vials
- For questions about temperature excursions, contact [Bavarian Nordic](#) at:
 - medical.information_NA@bavarian-nordic.com
- Resources
 - [Package-Insert-JYNNEOS \(fda.gov\)](#)*
 - [EZIZ Mpox Page](#)
 - Information for providers on accessing commercial product:
[ResourceforProviders_JYNNEOSonCommercialMarket.pdf \(eziz.org\)](#)

* See next slide regarding refrigerated shelf-life

Storage and Handling Refresher

- Storage Conditions
 - Keep frozen at -25°C to -15°C (-13°F to +5°F).
 - Store in the original package to protect from light.
 - Do not re-freeze a vial once it has been thawed.
 - Once thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) for 4 weeks*.
 - Do not use the vaccine after the expiration date shown on the vial label.
- * SNS doses and commercial lot #96867
 - * Once thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) for **8 weeks**
 - NOT consistent with package insert (4-week shelf-life in refrigerator)
 - [**EZIZ Mpox Page**](#)
 - [Extension of shelf life for SNS JYNNEOS vaccine stored at 2-8°C \(36 46°F\)](#)
 - [Extension of shelf life for commercial lots of JYNNEOS vaccine stored at 2-8°C \(36 46°F\)](#)

ACIP Mpox Update

ACIP Mpox Presentation

- Clade I mpox outbreak ongoing in Democratic Republic of the Congo
 - Travel related cases in surrounding countries
 - Few travel related cases in countries outside of Africa with limited spread to household contacts
 - No Clade I mpox cases identified in U.S.
 - Risk of Clade I mpox in U.S. is still considered to be low
 - Vaccination recommended for travelers with sexual risk factors to certain countries† irrespective of sexual orientation and gender identity
- Mpox workgroup reconvening
 - Will review NIH study about use of JYNNEOS in persons 12-17 years of age
 - Consider bringing to an ACIP vote
 - Anticipate presentations during February 2025 ACIP meeting

†[CDC: Clade I Mpox Outbreak Originating in Central Africa](#)

Clinical

Floria Chi, MD, MPH, CDPH

Advisory Committee on Immunization Practices (ACIP)

Meeting: October 23 – 24, 2024

Topics:

- COVID-19 Vaccines (Vote)
- RSV Immunizations: Maternal/Pediatric and Adult
- Influenza Vaccines (VFC Vote)
- Pneumococcal Vaccines (Vote)
- Meningococcal Vaccines (Vote, VFC Vote)
- Immunization Schedules – Adult and Child/Adolescent Revisions (Vote)
- Human Papillomavirus (HPV), Cytomegalovirus (CMV), Chikungunya, Mpox

[ACIP Meeting Information](#) | [Agenda](#) | [ACIP Recent Meeting Recommendations](#)

Additional 2024 – 2025 COVID-19 Vaccine Doses recommended for ≥65 years and immunocompromised

On October 23, 2024, ACIP and CDC made the following recommendations:

A **second dose of 2024 – 2025 COVID-19 vaccine** **should** be given 6 months* after their first dose to:

- **65 years and older**
- 6 months-64 years who are **moderately or severely immunocompromised**
 - Additional doses* (i.e., 3 or more) of 2024 – 2025 COVID-19 vaccine **may** be given to immunocompromised people 6 months – 64 years under **shared clinical decision making**.

*Minimum interval 2 months.

[ACIP Recommendations | CDC](#); [Clinical Guidance for COVID-19 Vaccination | CDC](#) (pending update)

COVID-19 Vaccine Routine Schedule

For **everyone 65 years and older**:

- 2 doses of 2024 – 2025 COVID-19 vaccine recommended at 6-month interval*
- If unvaccinated and receiving Novavax: 2 dose initial series, followed by 3rd dose of any COVID-19 vaccine 6 months* after 2nd dose.

*Minimum interval 2 months.

IMM-1396 COVID-19 Vaccine Timing Chart

COVID-19 Vaccine Timing 2024-25 –Routine Schedule			
For online version and details view Interim Clinical Considerations for Use of COVID-19 Vaccines . Schedule is subject to change.			
Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2024-25 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8* weeks ① ≥8 weeks ② If ≥2 prior doses, then: ≥8 weeks ①
	Moderna–Pediatric*	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 4-8 weeks ① If ≥2 prior doses then: ≥8 weeks ①
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months ① 2024-25 Moderna/Pfizer/Novavax
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	If 1 or more prior doses (of any of the brands), then*: Ages 12-64 years: ≥2 months ① 2024-25 Moderna/Pfizer/Novavax Ages 65+ years: ≥2 months ① 6 months§ ②
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax	1st Dose → 3-8 weeks** → 2nd Dose	
		6 months†	Ages 65+ years: Additional Dose Moderna/Pfizer/Novavax

* See [CDC recommendations](#) for children transitioning from a younger to older age group

† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.

** An 8-week interval may be preferable for some people, especially for males 12-39 years.

‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).

^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

§ Minimum interval 2 months.



COVID-19 Vaccine: Immunocompromised

For immunocompromised 6 months and older:

- Initial COVID-19 vaccine series (mRNA – 3 doses, Novavax – 2 doses)
- At least 2 doses of 2024 – 2025 COVID-19 vaccine at 6-month interval^{^*}
- Additional doses under shared clinical decision-making*

[^]One dose may be received as part of initial series. At least one dose should be received 6 months* after initial series.

*Minimum interval 2 months.

IMM-1396 COVID-19 Vaccine Timing Chart


COVID-19 Vaccine Timing 2024-25 If Moderately/Severely Immunocompromised									
Age	Vaccine	If unvaccinated:					If had any prior doses give 2024-25 doses:		
6 months–4 years	Pfizer Infant/Toddler	1st Dose	3 weeks	2nd Dose	≥8 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
5–11 years	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
	Pfizer–Pediatric	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
	Moderna–Adol/Adult (Spikevax)	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months [§]	Additional Dose(s)*	
	Novavax	1st Dose	3 weeks	2nd Dose			6 months [§]	Additional Dose(s)*	
<p>Additional Dose(s)* Timing:</p> <p>6 months–4 years: 1 prior dose: 3 w 1 ≥8 w 2; ≥2 prior doses: ≥8 w 1</p> <p>5–11 years: 1 prior dose: 4 w 1 ≥4 w 2; 2 prior doses: ≥4 w 1; ≥3 prior doses**: ≥8 w 1 (for ages 5+ yrs, Pfizer dose is also OK)</p> <p>12+ years: 1 prior dose: 3 w 1 ≥4 w 2; 2 prior doses: ≥4 w 1; ≥3 prior doses**: ≥8 w 1</p>									
<p>* Further doses may be given under shared clinical decision-making at a minimum interval of 2 months. See Table 2 for vial and dosage.</p> <p>** Ages 5-11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax.</p> <p>§ Minimum interval 2 months.</p>									

COVID-19 Vaccine: **Immunocompromised**

- **Prior** guidance recommended one dose of 2023 – 2024 COVID-19 vaccine for immunocompromised individuals, a second optional dose, and additional optional doses at the healthcare provider's discretion.



- **New** guidance strengthens the recommendation for multiple doses of 2024 – 2025 COVID-19 vaccine for immunocompromised individuals



[ACIP Shared Clinical Decision-Making Recommendations | ACIP | CDC](#)

COVID-19 Vaccines: Clinical Considerations


- **Novavax:** If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024 – 2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer) may be administered.
- **Age transitions:** If a person moves to an older age group between vaccine doses, vaccinate based on their age on the day of vaccination.
 - For children who transition from 4 to 5 years old and for immunocompromised children who transition from 11 to 12 years old, the option to administer the lower dosage is no longer authorized.

[Clinical Considerations for the use of 2024-2025 COVID-19 Vaccines in the United States](#)

COVID-19 Hospitalizations Highest Among Persons ≥ 75 years, Followed by <6 months and 65-74 Years

Weekly rates of COVID-19-associated hospitalizations — COVID-NET, March 2020–September 2024


[CDC Presentation](#)



COVID-19 Vaccine Effectiveness (VE) Update






VISION: VE of 2023-2024 COVID-19 vaccine against *hospitalization and critical illness* among adults aged ≥ 18 years

September 2023 – August 2024




COVID-19 Vaccine Effectiveness Update

Effectiveness of **2023-2024 COVID-19 vaccines** against critical outcomes in immunocompetent adults ≥65 years, Medicare and VISION data


Outcome	Analysis	Vaccine effectiveness, % (95% CI)	
Thromboembolic events*	Medicare, ESKD adults ≥65y, 2023-2024 vaccine, median follow-up days=74	53 (23-71)	
Death	Medicare, ESKD adults ≥65y, 2023-2024 vaccine, median follow-up days=104	47 (15-67)	
ICU admission/death	VISION, adults ≥65y, 2023-2024 vaccine, median follow-up days=34	69 (57-78)	
	VISION, adults ≥65y, 2023-2024 vaccine, median follow-up days=89	56 (42-68)	
	VISION, adults ≥65y, 2023-2024 vaccine, median follow-up days=149	43 (18-60)	

Abbreviations: ESKD = end stage kidney disease; y = years; IMV = invasive mechanical ventilation; ICU = intensive care unit



RSV Immunizations: Maternal & Pediatric

- Recommendations have not changed.
- ACIP encourages immunization **ideally during the birth hospitalization** for infants born during October through March who are not protected by maternal RSV vaccine.



[CDC PowerPoint Presentation](#)

RSV Immunizations: Maternal and Pediatric

- Merck presented safety and immunogenicity data for its infant RSV monoclonal antibody product, clesrovimab.
 - Further discussion planned at next ACIP meeting (February 2025).
- Vaccine Safety Datalink (VSD) studies on maternal RSV vaccine:
 - Vaccination was not found to be associated with increased risk for preterm birth or small for gestational age (SGA).
 - Association between vaccination and hypertensive disorders of pregnancy (preeclampsia/eclampsia/HELLP syndrome) unclear, currently studying this and other outcomes.

[Clesrovimab Presentation](#); [RSV Mat/Ped WorkGroup Presentation](#); [Maternal RSV Vaccine Safety Presentation](#)

RSV Immunization Communication Templates – NEW!

- [Provider Letter and Robocall Script Templates for Maternal and Pediatric RSV Immunization](#) (Spanish included)

Template Portal Script for Prenatal Patients

Dear Patient,

We strongly recommend that you get vaccinated against respiratory syncytial virus (RSV) to protect yourself and your baby as you near the end of your pregnancy. RSV is a serious respiratory illness that is the leading cause of hospitalization of babies in the U.S. RSV vaccine (Abrysvo) is recommended for those 32-36 weeks pregnant, now through January.

The protection you get from this vaccine passes on to your baby, continuing after birth when your baby is most vulnerable. RSV vaccine has been thoroughly tested and proven to be safe for you and your baby and can be given at the same time as other prenatal vaccines, including flu, COVID-19, and Tdap.

If stocking RSV vaccine, end with:

Protect yourself and your baby as soon as possible. Contact us today to schedule your RSV vaccine.

For more information, see [Should I Get the RSV Vaccine during Pregnancy?](#)

If not stocking RSV vaccine, end with:

Protect yourself and your baby as soon as possible. We recommend that you contact your local in-network pharmacy to make an RSV vaccine appointment today!

For more information, see [Should I Get the RSV Vaccine during Pregnancy?](#)

Spanish version:

Estimado paciente,

Le recomendamos ampliamente que se vacune contra el virus respiratorio sincitial (VRS) para protegerse a sí misma y a su bebé a medida que se acerca el final de su embarazo. El VRS es una enfermedad respiratoria grave y la principal causa de hospitalización de bebés en los EE. UU. La vacuna contra el VRS (Abrysvo) se recomienda para las mujeres que tienen entre 32 y 36 semanas de embarazo, desde ahora hasta enero.

La protección que usted obtiene con esta vacuna se transmite a su bebé y continúa después del nacimiento, cuando su bebé es más vulnerable. La vacuna RSV ha sido estudiada exhaustivamente y se ha demostrado que es segura para usted y su bebé. También se puede administrar al mismo tiempo que otras vacunas recomendadas durante el embarazo, incluyendo la vacuna contra la influenza (la gripe), el COVID-19 y Tdap.

RSV Immunizations: Adult

- Workgroup reviewed
 - Current RSV vaccine safety surveillance data
 - Coadministration of RSV vaccines with other adult vaccines
 - Clinical trial evidence on protein subunit RSV vaccination in immunocompromised

Brand Name	Composition	Recommended Groups
ABRYSSVO® (Pfizer)	Protein	<ul style="list-style-type: none">• Older Adults*• Pregnant persons to protect infants
AREXVY (GSK)	Protein + adjuvant	Older Adults**
mRESVIA (Moderna)	mRNA	Older Adults

*[ABRYSSVO](#) and **[Arexvy](#) are FDA approved, but not CDC recommended, for younger adults at increased risk of severe RSV


[ACIP Presentation: Adult RSV Workgroup Interpretations \(10/24/24\)](#)

Estimated RSV-Associated Outcomes Preventable over 3 seasons vs. attributable risk of Guillain-Barré Syndrome

Per 1 Million Persons Vaccinated with Protein Subunit RSV Vaccine:

Adults Aged ≥75 Years,
General Population

Adults Aged 60–74 Years³ at Increased
Risk of Severe RSV Disease



0–18⁴ attributable cases of GBS

[ACIP Presentation: Adult RSV Workgroup Interpretations \(10/24/24\)](#)

Adult RSV Recommendations Remain the Same

- **Adults aged ≥ 75 years should receive a single dose of RSV vaccine.**
- **Adults aged 60-74 years old who are at increased risk of severe RSV disease should receive a single dose of RSV vaccine.**
- Benefits of RSV vaccination outweigh risks, including potential risk of GBS and protein-based vaccines, among the populations for whom vaccination is recommended.
- Coadministration of RSV vaccine and other recommended adult vaccines, including influenza and COVID-19 vaccine, is acceptable.

[ACIP Presentation: Adult RSV Workgroup Interpretations \(10/24/24\)](#)

Influenza Vaccines

VFC Vote: ACIP updated the Influenza Vaccines VFC Resolution to include high-dose and adjuvanted inactivated influenza vaccines as options for 18-year-old solid organ transplant recipients on immunosuppressive medications.

Enhanced influenza vaccine recommendations:

- **Solid organ transplant recipients 18-64 yrs.** on immunosuppressants: any age-appropriate vaccine, **including all enhanced options**
- **Age ≥ 65 yrs: Preferentially** recommended to receive any enhanced vaccine

Type	Description	Licensed Ages	Brand Name
Adjuvanted	Contains MF59 adjuvant	65+ years	FLUAD Adjuvanted
High-dose	4x hemagglutinin vs standard dose	65+ years	Fluzone High-Dose
Recombinant	3x hemagglutinin vs standard dose	18+ years	FluBlok*

*FluBlok not currently in VFC

[2024-2025 Influenza Vaccine ACIP Recommendations | MMWR](#)

2023 – 2024 Influenza Vaccine Effectiveness

- Vaccination with a 2023 – 2024 influenza vaccine **reduced the risk** of influenza outpatient visits and hospitalizations among children, adolescents, adults, and the elderly.
- Preliminary end-of-season estimates similar to interim 2023 – 2024 influenza vaccine effectiveness (VE) estimates from February 2024:
 - Pediatric VE:
 - Outpatient visits: 59-67%
 - Hospitalizations: 52-61%
 - Adult VE:
 - Outpatient visits: 33-49%
 - Hospitalizations: 41-44%

[ACIP PowerPoint Presentation; Interim 23-24 Flu VE Estimates | MMWR](#)

Pneumococcal Vaccines

- **Vote:** ACIP and CDC now recommend a pneumococcal conjugate vaccine (PCV) for all PCV-naïve adults **aged ≥ 50 years**
- Lowers age-based recommendation from prior age (was ≥ 65 years)
- Risk-based recommendation now for adults 19 – 49 years (was 19 – 64 years)
- No preference among adult pneumococcal vaccine options (PCV21, PCV20, PCV15 + PPSV23)
- CDC will release additional guidance for patients who previously received pneumococcal doses.

[ACIP Presentation: Pneumococcal \(10/23/24\)](#)

Meningococcal B Vaccines

- **Vote:** ACIP and CDC now recommend MenB-4C (Bexsero®) be administered:
 - As a 2-dose series at 0 and 6 months for healthy adolescents and young adults aged 16–23 years based on shared clinical decision-making for the prevention of serogroup B meningococcal disease
 - As a 3-dose series at 0, 1–2, and 6 months when given to persons aged ≥10 years at [increased risk for serogroup B meningococcal disease](#)
- **VFC Vote:** Approve the updated Meningococcal Vaccines VFC Resolution with the administration schedules listed above.
- This updated recommendation aligns with [Bexsero® FDA licensure](#) and harmonizes with MenB-FHbp (Trumenba) recommendations.

[ACIP Presentation: Meningococcal \(10/24/24\); CDC Meningococcal Vaccination for Healthcare Providers](#)

Meningococcal B Vaccines

- The 3-dose series (doses administered at 0, 1–2, 6 months) may be used to optimize rapid protection for those who initiate the vaccine series less than 6 months prior to period of increased risk– e.g., when series initiation occurs within 6 months of college matriculation
 - Would apply to MenB-4C (Bexsero) and MenB-FHbp (Trumenba)
- No recommendation to recall persons previously vaccinated with MenB-4C (Bexsero) at 0, ≥ 1 month
- Persons should continue with booster vaccination as previously recommended
- Reminder: MenB vaccines from different manufacturers are NOT interchangeable.

[ACIP Presentation: Meningococcal \(10/24/24\); CDC Meningococcal Vaccination for Healthcare Providers](#)

2025 Immunization Schedules

- **Vote:** ACIP & CDC approve the 2025 immunization schedules:
 - Recommended Child and Adolescent Immunization Schedule
 - **Changes include:** COVID-19, Haemophilus influenzae type b (Hib), Influenza, Meningococcal B
 - Recommended Adult Immunization Schedule
 - **Changes include:** COVID-19, Influenza, Meningococcal, Pneumococcal, RSV

[ACIP Presentation: 2025 child and adolescent schedule revisions; 2025 adult schedule revisions](#)

Human Papillomavirus and Cytomegalovirus

- **Human Papillomavirus (HPV) Workgroup** is reviewing:
 - Reducing number of doses in HPV vaccination series
 - [WHO 2022 Recommendations](#): 2 doses for persons ≥ 9 years, with option for single-dose through age 20 years, except those immunocompromised
 - Wording of age 9 years for routine vaccination
 - Plan to share more in February 2025 ACIP, anticipate future votes
- **Cytomegalovirus (CMV) Workgroup**
 - Will present on burden of CMV in 2025
 - Congenital CMV is most common infectious cause of neurodevelopmental disabilities in U.S. children; affecting ~4,000 children per year
 - 1 mRNA vaccine in clinical trials


Chikungunya






- Live attenuated vaccine (IXCHIQ, Valneva) recommended:
 - For persons ≥ 18 years traveling to a country or territory with an outbreak
 - For laboratory workers with potential for exposure to virus
- Future workgroup policy discussions:
 - Residents in U.S. states and territories with endemic infection
 - Younger age groups
 - 2nd vaccine, recombinant protein-based, anticipated licensure in Feb 2025

[ACIP Presentation Slides \(10/23/24-10/24/24\)](#); [CDC Chikungunya Vaccine for Healthcare Providers](#)

[2024-25 Fall-Winter Immunization Guide](#) | [Spanish](#) – **NEW!**

VACUNAS OTOÑO-INVIERNO



	¿Quiénes pueden vacunarse?	¿Qué vacunas se recomiendan?	¿Cuándo debo recibirla?
Influenza	6 meses y mayores 	Las vacunas contra la influenza están disponibles como inyección o aerosol nasal. La vacuna contra la influenza previene millones de enfermedades y visitas al doctor por la influenza cada año.	Lo ideal es septiembre u octubre, pero ponerse al día más tarde también puede ser útil.
COVID-19	6 meses y mayores 	Las vacunas contra el COVID-19 actualizadas protegen contra enfermedades graves y la muerte por COVID-19.	Vacúnese ahora si han pasado al menos dos meses desde su última dosis de COVID-19.
VRS (Personas Embarazadas)	Personas embarazadas entre las 32-36 semanas de embarazo que no se han vacunado contra el VRS durante un embarazo anterior. 	La vacuna prenatal contra el VRS ayuda a reducir el riesgo de enfermedad grave por VRS en los bebés (ayuda a proteger al bebé meses después de nacer).	Se recomienda entre las 32 y 36 semanas de embarazo, de septiembre a enero, para ayudar a proteger a su bebé durante la temporada del VRS.
VSR (Bebés y niños pequeños)	Todos los bebés desde el nacimiento hasta los 8 meses y los niños de 8 a 19 meses con alto riesgo de enfermedad grave por VRS. 	La inmunización contiene anticuerpos preventivos que ayudan a combatir las infecciones por VRS y tienen una eficacia del 90% en la prevención de la hospitalización por el VRS.	Antes o durante la temporada del VRS, usualmente entre octubre a marzo.
VRS (Adultos mayores)	Mayores de 75 años y adultos entre 60-74 años con mayor riesgo de enfermedad grave por VRS. 	La vacuna contra el VRS protege a los adultos mayores contra la enfermedad por VRS.	Disponible todo el año. Los CDC animan a los proveedores de salud a maximizar los beneficios de la vacuna contra el VRS ofreciéndola a finales de verano o principios de otoño. No se recomiendan dosis de refuerzo en este momento.

Nota: puede recibir las vacunas contra la influenza, COVID-19 y VRS durante la misma cita.

¿Dónde vacunarse?

- Póngase en contacto con su doctor, farmacia local o visite [MyTurn.ca.gov](#).
- ¿Necesita más ayuda? Póngase en contacto con su [departamento de salud local](#).
- Los niños que reúnen los requisitos de Medi-Cal, los indios americanos/nativos de Alaska, sin seguro o con seguro limitado pueden recibir vacunas sin costo a través del [Programa de Vacunas para Niños](#).

Gracias a Katelyn Jetelino, PhD, MPH y Caitlin Rivers, PhD, MPH por permitir que el CDPH adapte este recurso.

Departamento de Salud Pública de California | Sección de Inmunización

IMM-14815 (10/24)

CA Bridge Access Program

Maria Volk, CDPH

CA BAP Funding and Ordering 2024 – 2025

Funding: Section 317 COVID-19 funding supports ordering for vaccines provided through the California Bridge Access Program.

FFY	317 Funds	Overall Vaccine Ordering Limits	Ordered Doses	% Budget Consumed
2024 – 2025	5.9M	69K	*19,270	*28%

*As of 10/29/2024

Depleted CA BAP Seasonal Allocations?

- Any pending orders for COVID-19 brands that the LHD no longer has inventory to approve will need to be rejected.
- Providers may then request a new order of the available product or the LHD may submit the order on behalf of the provider.
- Providers will be notified if a new product is being requested for them due to storage unit preparation.**

COVID-19 Vaccine Product Guide

COVID-19 Vaccine Product Guide

Check vaccine labels and FDA materials before use to avoid mix-ups.

[Package inserts and EUA fact sheets](#) supersede info on vials and carton.

Pfizer

Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Comirnaty 12+ years	Comirnaty 12+ years
		Single-Dose Vial 2024-25 Formula image not available	
2024-25 Formula	2024-25 Formula		2024-25 Formula

Packaging	Yellow Cap	Blue Cap	Pre-Filled Syringe	
Doses Per Vial	3 doses	1 dose	1 dose	1 dose/syringe
Carton Size	30 doses	10 doses	10 doses	10 doses
NDC-Unit of Sale (carton)	59267-4426-02	59267-4438-02	00069-2403-10	00069-2432-10
NDC-Unit of Use (vial/syringe)	59267-4426-01	59267-4438-01	00069-2403-01	00069-2432-01
CVX Code	308	310	309	309
CPT Code	91318	91319	91320	91320
Program Availability	VFC	VFC	Not available	VFC, CA BAP
Min. Standard Order*	30 doses	10 doses	N/A	10 doses

Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.

Shipping	Ships from manufacturer with dry ice between -90°C and -60°C (-130°F to -76°F)	2° to 8°C (36°F to 46°F)
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)	
Thermal Shipper		
Freezer		
Refrigerator	Up to 10 weeks at 2°C to 8°C (36°F to 46°F). Do not refreeze. Write the use-by date on carton—not to exceed expiration.	Until expiration at 2°C to 8°C
Expiration Date	Check the date on the product/carton, or for thawed products refer to the written use-by date.	Check label.

Administration

Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute	N/A
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time	Carton/Vial: Up to 2 hours at 2° to 8°C (36°F to 46°F) (Do not refreeze)			N/A
Room Temp Thaw Time	Vial: 30 minutes at up to 25°C (77°F) (Do not refreeze)			N/A
Total Time at				

Vaccine Pharmacy Update

Edward Salaguinto, PharmD, RPh

Medi-Cal Rx COVID-19 Vaccine Reimbursement

- COVID vaccines will remain a pharmacy benefit for all Medi-Cal members.
 - Non-VFC pharmacies
 - Effective through **December 31, 2024** (under the *PREP Act), non-VFC pharmacies will be reimbursed for COVID claims for members 3 years+. Members under 3 years should be redirected to VFC providers (including pharmacies).
 - Effective **January 1, 2025**, non-VFC pharmacies will be reimbursed for COVID claims for members 19 years+.
 - VFC pharmacies
 - Effective **August 30, 2024**, VFC pharmacies will be reimbursed for COVID claims for members 0 through 18 years.
- The enhanced \$40 reimbursement associated with the COVID-19 vaccine administration fee transitioned to the standard vaccine administration fee effective **October 1st, 2024** (the end of the **ARP Act) for all providers.

* PREP Act: Public Readiness and Emergency Preparedness Act

** ARP Act: American Rescue Plan Act

Questions? Email: MediCalRxEducationOutreach@primetherapeutics.com


Vaccine Management

Josh Pocus, My Turn

Maria Volk, myCAvax

What's New in My Turn? – Release 54

New updates for Patients, Clinic Managers, and Vaccine Administrators launched on **Wednesday, October 30, 2024!**



Release Highlights

- ✓ Patients receive a satisfaction survey via email the day after their appointment
- ✓ Added an error message if the 'Clinic End Date' exceeds one year from the start date on the Testing site information form
- ✓ Patients can see updated error messages when no clinics are found in the search on the 'Select a location' page
- ✓ Renamed the 'Walk-ins welcome' tag to 'Accepts walk-ins'
- ✓ Enhanced the Testing site information form

My Turn Public

Release Highlights

- ✓ Disabled the 'This contact is also a Prescribing Provider' checkbox after three providers are added, as only three can be created on the digital enrollment flow
- ✓ Displayed all fields in the 'Clinic Name and Location' section on the clinic creation flow
- ✓ Renamed the 'Set Clinic Visibility' section to 'Vaccine Locator,' repositioned it, and renamed the toggle to 'Show on My Turn Vaccine Locator' on the clinic creation flow
- ✓ Renamed the 'Walk-ins welcome' checkbox to 'Accepts walk-in patients' on the clinic creation flow, 'Clinic' page, and Vaccine Locator form
- ✓ Modified 'Details' tab on the 'Clinic' page with updated checkboxes and fields
- ✓ Added an error message if the 'Clinic End Date' exceeds one year from start date on the clinic creation flow and 'Clinic' page
- ✓ Added new Covid-19 and Flu products on the CQE flow
- ✓ Added new 'Route' and 'Injection Site' values on the CSV / Inline bulk upload flows
- ✓ Added an error message if no vaccine is selected when submitting the Vaccine Locator form
- ✓ Clinic owner receives deactivation reminder emails for inactive clinics

My Turn Clinic

Vaccine Locator – Opt-in Instructions

How to Opt-In:



1. Log into myCAvax
2. Navigate to “Provider Locator” page
3. Navigate to the sub-page “My Turn Vaccine Locator Opt-In”
4. For each location, click the blue “Manage Vaccine Locator Form” button
5. Fill in the fields and press submit

The screenshot shows the myCAvax website interface. At the top, there's a navigation bar with links: Home, My Programs, My Turn (with a dropdown arrow), Vaccine Orders, Program Locations, and More (with an upward arrow). A search icon, a notification bell, and a user profile icon are on the right. A dropdown menu is open under 'More', showing options: Enrollment, Reports, myCAvax Dashboard, Provider Locator (highlighted with a purple box and a blue circle '2'), and Knowledge Center. The main content area is titled 'Provider Locator' and includes instructions. A sub-link 'My Turn Vaccine Locator Opt-In' is highlighted with a purple box and a blue circle '3'. Below this, there's a section 'Opt-in to My Turn Vaccine Locator (Public-facing)' with a description. A 'My Locations' section contains a 'Search by Locator Status' dropdown (set to 'Inactive') and 'Search' and 'Reset' buttons. Below the search, there's a table with columns 'Location' and 'Vaccine Locator Status'. The first row shows 'GVHC - 889 Abrego St - HS' and 'Inactive'. To the right of the table, there's a dropdown for 'Vaccine Locator' (highlighted with a blue circle '4') and a button 'Manage Vaccine Locator Form' (highlighted with a purple box).

NOTE: To opt-out, click the “manage form” button for the location and select “No we do not accept new patients.” Then submit.

Vaccine Locator – Opt-In Today!

Program Locations that have Opted-In:



Please take some time to opt-in, **preferably right now!** We want patients to be able to find you.

We want to congratulate **Los Angeles County** for their participation and being the top county with **131 Locations** opted-in!

Data as of 10/31/24



Thank you for opting into the Vaccine Locator. By doing so, you are ensuring that patients can easily find your locations. Your participation is invaluable in **helping patients access the care they need.**

The Alliance For Community Wellness	La Maestra Community Health Centers
Family HealthCare Network	WellSpace Health
ARYA MEDICAL GROUP	AAA Comprehensive Healthcare
Dizon Medicine Urgent Care	Arlington Prescription Pharmacy
First Pediatrics Medical Group	Prime Family and Walk-In Clinic
Niloo Medical Group INC	Valley Healthcare Centers
El Proyecto del Barrio, Inc	Pacific Central Coast Health Centers
AltaMed Health Services Corporation	Golden Oak Pediatrics
Family Health Care Centers of Greater Los Angeles	yasmeen gangani pediatrics
Emanate Health Med Group Pediatrics	Q-Bit Wellness
Public Health Division	County of Los Angeles Department of Public Health
Coppertower Family Medical Center Inc dba	Moreno Valley Physicians Associates, A Medical Corporation
Alexander Valley Healthcare	Hollywood Sunset Free Clinic
Mono County Health Department	Blessing Community Health Center
Humboldt County Public Health	La Clinica de La Raza
San Benito County Public Health Services	DR. SATEY PEDIATRIC ADOLESCENT MEDICAL CLINIC
San Bernardino County Department of Public Health	San Lucas Pediatric Clinic, Inc.
Napa County Health and Human Services Agency	Pediatrics R US INC
County of Placer	J. Shafai, M.D., Inc.
Fresno County Department of Public Health	Dr. Naomi Sato
Sacramento County Public Health	Clinica Medica Familiar- PHN, Inc.
Kings County Department of Public Health	Merced Faculty Associates Medical Group, Inc
Huong Quy, D.O.	CRESENCIA D BANZUELA MD. INC.
S4 Pharmacy, INC.	Arnold J. Blustein, MD, Inc.
Riverside University Health System-Community Health Center	DEL ROSARIO MEDICAL CLINIC, INC.
Angeles Medical Clinic	Pamela V. Atienza, MD, A Professional Medical Corporation
Loan Truong	San Juan Pediatrics
National City Fire Department	Greg M Oji
DE ANZA CLINIC	ABC Pediatrics Medical Center
DAP Health	SARASA KUMAR, M.D, INC
Clover Pharmacy	NASSER AZIZ-ZADEH M.D.
Community Medical Centers, Inc.	

myCAvax Release Roadmap

Past Release September 19, 2024 (R50)

Release 50

All Programs

- ✓ Supplemental Orders (Live as of 9/4)
- ✓ Self Service – Enable Organization Vaccine Coordinator
- ✓ Returns and Waste – Prevent excess Return Labels from being sent
- ✓ Prevent duplicate or invalid lot numbers on orders
- ✓ Provider Orders Will be sorted by most recently created
- ✓ Transfers updates including:
 - ✓ Batch accept/reject and layout updates
 - ✓ Updated language and additional information in the list view page
 - ✓ Ability for providers to update information when accepting a transfer
- ✓ Order processing enhancements

Current Release October 16, 2024 (R51)

Release 51

VFC

- ✓ Bulk Allocation

VFC/VFA/317

- ✓ Corrections Needed orders will handle rejected line items and expired lots
- ✓ Field Reps will be notified when an order is placed with an open hold
- ✓ Only VtrckS Relevant changes will be sent to VtrckS
- ✓ Pending Status will now require a status reason
- ✓ Internal Comments will be saved as notes on an order instead of in the text box
- ✓ Providers will see variance columns when creating orders
- ✓ Providers will be able to save progress on draft and corrections needed orders
- ✓ Provider will only be able to have one open order at a time

Future Release November 13, 2024 (R52)

Release 52

VFC/VFA/317

- ✓ 2025 Recertification for VFC
- ✓ Enhancements to the VFA and LHD 317 Recertification
- ✓ Duplicate 'Staff Management Requests' will be prevented
- ✓ CDPH will have the ability to 'Expire' Orders manually

What's New in myCAvax? – Release 51

New updates for providers launched on **October 16, 2024!**

Release Highlights



Providers

Ordering

- ✓ New order requests cannot be submitted if a Draft order exists.
- ✓ Update order lines and save changes in the Draft or Corrections Needed orders without resubmission by using 'Save Progress' button.
- ✓ Save Draft or Corrections Needed orders without completing all fields.

Variance

- ✓ New 'Variance' column is visible when placing a new order request.

Account Management

- ✓ If a duplicate contact is found while using the 'Add New Contact' button, the newly assigned role will be updated pending review and approval.
- ✓ Corrections Needed orders can be resubmitted, even if some Order Line Items are 'Rejected'.

R51: Updating Existing Orders in ‘Draft’ or ‘Corrections Needed’ Status

- Providers can update order lines and save changes using the ‘Save Progress’ button when the batch order is in ‘Corrections Needed’ or ‘Draft’ status without resubmitting or changing batch order status.
- This ensures that changes to order lines and accountability records are recorded. Providers can also save changes even if fields are missing.

DetailsOrder Line ItemsAccountability RecordsShipmentsChatter

Order Request
Order Number B-042631

Program Location
Reshma's Unicorn Island - Vaccines for Children

Program
Vaccines for Children

Provider Type
Private Hospital

PIN
123456232

Status
Corrections Needed

Status Reason
Accountability error

Submitted Date
2024-07-31

Order Line(s)

Account for every dose of VFC-supplied vaccine ordered and received by the provider location.

Vaccine ProductsVFC On-hand InventoryVFC Doses administeredInventory SummaryOrder size

Vaccine product	Quantity	Lot number	Expiration Date / Beyond use date	Qty since last order	Estimated inventory	Variance	Recommended Order size	Doses requested	Order size reason	Please specify "Other"
Infanrix Single Dose Syringes - 10 Per Box	50	QGH878	6/29/2027	40	50	0	30	20	Special Events	
Kinrix Single Dose Syringes - 10 Per Box					0			0	-Select-	

Comments
Corrections are done.

☐ I confirm the shipping hours above are accurate.

Temporary Closure

If your location will be temporarily closed and cannot accept deliveries, please enter the dates below. This will not affect your current shipping hours. Updating temporary closure dates is account-wide and will affect all programs.

☐ Enable temporary closure

Cancel

Save Progress

Submit Order

R51: Saving New Draft Orders

VFC

VFC - Order Request

Step 1 - Select Account and Product

To change the program selected, navigate back to the [Vaccine Orders page](#).

Program Location

MNHC - Excelsior Clinic - Vaccines for Children

Select Location, Provide Inventory and Doses Administered for Vaccines Listed.

• Ensure the current VFC inventory in your vaccine storage units matches the On-hand Inventory you enter.

• Your VFC Doses Administered inventory must match the immunization registry (CAIR/Healthy Futures).

• View the provider inventory link below to account for every dose your location has received. If your calculated provider inventory does not match, please ensure that you have reported all transfers, waste events, and returns prior to this order request.

Next Order Due Date (approximate)

Provider Inventory

Practice Volume & Order Frequency

October 31, 2021

[View Provider Inventory](#)

Medium (every 2 months)

Vaccine Products

VFC On-hand Inventory

VFC Doses administered

Provider inventory

Order size

Vaccine product	*Quantity	Lot number	Expiration Date / Beyond use date	*Qty since last order	Estimated Provider inventory	Variance	Recommended Order size	*Doses requested
VFC Shared COVID								0
VFC Shared Flu								0
VFC Shared Outbreak								
VFC Shared Routine								
RAAmet 2024-2025 Intranasal Spray- 10 Per Box								

Cancel


Save Progress

Submit Order

Providers can click the new ‘Save Progress’ button to save changes to order line items without resubmitting or click the ‘Submit Order’ button to submit the draft order.

R51: Submitting 'Draft' Orders

Providers cannot submit a 'New Orders' request if a 'Draft' order already exists. They will see an error message containing a link to the existing draft order.



NOTE: Special thanks to all providers that made us aware of the issue we were encountering last week with this feature. The issue has now been resolved.

R51: Viewing the ‘Variance’ Column as a Provider

- To assist with accurate vaccine inventory reporting, providers can view a new ‘Variance’ column when creating a vaccine order for VFC, VFA, or LHD 317 programs. Variance is the difference between the system calculated on-hand inventory and the provider reported on-hand inventory.
 - If a Variance displays (like the one below), check your Provider Inventory for that Product and make sure your Waste and Returns, Excursions and Transfers are up-to-date.

Vaccine Products		VFC On-hand Inventory		VFC Doses administered		Provider inventory		Order size			
Vaccine product	*Quantity	Lot number	Expiration Date / Beyond use date	+ -	*Qty since last order	Estimated Provider inventory	Variance	Recommended Order size	*Doses requested		
Shared Products	VFC Shared COVID	80	KK9E	1/1/2034	+	100	-100	Over by 180	60	60	Clear Row
	VFC Shared Flu	0			+	0	0	0	0	0	Clear Row
	VFC Shared Outbreak	0			+	0	0	0	0	0	Clear Row

myCAvax – Known Issues and Workarounds



Known Issues

Shipping Incidents pulling all Vaccines in Order

- ✓ When a provider submits a shipping incident in myCAvax and selects the related order, it would automatically pull every single vaccine product in the order even if only 1 vaccine product was affected.

File size limits when uploading excursions in myCAvax

- ✓ Providers have been encountering difficulties when trying to upload excursion documents in myCAvax that exceed the file size limit permitted in the system.



Workaround / Next Steps

- ✓ Providers should 'un-select' or 'uncheck' all vaccine products that were not affected in the shipping incident.
- ✓ Currently, the file size limit in myCAvax is 3 MB. You will be unable to properly submit your Excursion report if your file size exceeds 3 MB. In that case, upload a reduced file under 3 MB to submit the report and upload larger file(s) post-submission. Refer to the Uploading Temperature Data Reports section in the 'Recording Temperature Excursions' Job Aid to learn more about uploading additional documents after submission.

myCAvax – Known Issues and Workarounds



Known Issues

Deleting Incorrect Excursion Events

- ✓ Providers are unable to delete incorrect excursion events from the system. If there's the need to delete one, providers must contact the VFC Customer Service Center for assistance.

Providers unable to report multiple excursions within the same report

- ✓ This is something providers were able to do in SHOTS through MyVFCvaccines. Some providers may experience multiple temperature excursions within the same day or within a couple of days. Providers don't want to have to submit a new report for each excursion if affected inventory is all the same.



Workaround / Next Steps

- ✓ CDPH gathers all excursion events that need to be deleted and have them removed / cleaned up by the next myCAvax release.
- ✓ Providers should submit **one report** and report the coldest temp within the time frame as the minimum temperature and the warmest temp within the time frame as the maximum temperature. Then they will report the date and time of the first excursion and ensure that total time out range is the cumulative total time for all temp excursions. In the 'Comments' section, they should note that they had multiple cold / warm excursions within a certain timeframe.

Upcoming Vaccine Shipment Holds for November 2024

Monday	Tuesday	Wednesday	Thursday	Friday
October 28	29	30	31	November 01
04	05	06	07	08
11	12	13	14	15
Veteran's Day Holiday Hold - Vaccine Delivery Blackout				
18	19	20	21	22
25	26	27	28	29
			Thanksgiving Holiday Holds – Vaccine Delivery Blackout	

- Providers must update hours in myCAVax for any holiday or temporary closures to prevent shipment incidents during closures.
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

Novavax Vaccine – Important Reminders (1 of 2)

- Novavax vaccine doses currently being shipped have an expiry of November 30, 2024. **However, there are earlier shipped doses that expired on Thursday, October 31, 2024.** Doses will expire on that date.
- Providers should continue to use this vaccine right up until expiry date.
- Expired doses should be reported as expired waste in myCAvax and returned to McKesson, per usual.

Novavax Vaccine – Important Reminders (2 of 2)

- Novavax will be requesting a shelf-life extension for doses that have an expiry on November 30, 2024, and beyond during the respiratory virus season. CDPH will notify providers if/when shelf-life extensions are granted.
- To minimize vaccine wastage, we encourage placing smaller, more frequent orders and limiting quantities to the amount of vaccine that can be utilized within a two-week period.
- An [Expiration Look-Up Tool](#) is available for providers to check for most up-to-date information about expiry administration.

We Need Your Help with McKesson Cooler Returns!

- Providers receive these **EcoFlex 96** reusable coolers with all frozen and some refrigerated vaccine shipments.
 - Some of the benefits of these coolers are:
 - Minimizing vaccine wastage by improving cold chain maintenance during shipping
 - Sustainable solution reducing landfill
- Each cooler contains flyers with step-by-step directions for providers, including how to request a UPS pick up if the provider is not part of a regular route.




Please return these **EcoFlex 96** coolers using the enclosed pre-paid UPS shipping label (located inside the top portion of the cooler) so they can be refurbished.

Reminder: Submit Feedback in myCAvax

- Feedback is important to help us understand what's working well, what are some existing pain points and challenges you are encountering while using myCAvax.
- Please take the time to submit feedback using the 'Rate your experience' pop-up window. You are helping us **continue to refine and enhance myCAvax for you!**

Examples of feedback we have received:



The screenshot shows a feedback form titled "Rate your experience". Below the title, it says "Your feedback will help us make improvements in future". There are five yellow stars for rating. Below the stars, it says "Please provide your general feedback(optional)" and there is a text input field. At the bottom right, there is a red "Submit" button.

"So much help with the suggest order quantity."

"I like the feature to recommend order size and the ability to see expected inventory when placing order rather than after getting a denial."

"I liked added warnings before order is summited."

"More time needed to enter the information. You logged me out once and i lost all the information that i had entered."

"Allow to save information when toggling."

"MyVFCvaccines ordering portal prefilled lot number and expiration date information. Can they bring back this feature. Also helped ensure lot number and expiration date were accurate."

Viewing Support Resources

The image shows a screenshot of the EZIZ website, which is a one-stop shop for immunization training and resources. The website features a navigation menu on the left with links to Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, Training & Webinars, Clinic Resources, and Patient Resources. The main content area displays a banner for "Move to myCAVax" and a section titled "VFC vaccine ordering moved to myCAVax on June 10, 2024!". Below this, there is a detailed announcement about the transition from MyVFCvaccines to myCAVax, including a list of reminders for providers and instructions for logging in. A "Log in to myCAVax!" button is also visible. To the right of the website screenshot is a document titled "VFC Provider Training FAQs v.2_06.03.24". The document contains a table of contents with links to various sections, including "VFC Provider Training FAQs", "VFC providers through the transition from MyVFCvaccines to myCAVax", "For the latest transition updates, visit EZIZ", "be directed to related FAQs", "ment", and "7".

View VFC training recordings, decks and FAQs on [EZIZ's page](#) – your one-stop shop for immunization training and recordings.

For Program and Policy needs, you can contact the VFC Customer Service Center at (877) 243-8832 or via email to MyVFCvaccines@cdph.ca.gov. For myCAVax Technical Support, contact the Provider Call Center by calling the VFC Customer Service Center and selecting option 9 on the phone tree, or via email to myCAVax.HD@cdph.ca.gov.



Resources and Q&A

Leslie Amani and CDPH Subject Matter Experts



Updates to LTCF Flyer

- [Protect Against Flu, RSV, and COVID-19 poster](#) and 15 translations now updated!
 - [Spanish](#) | [Tagalog](#) | [Chinese](#) | [Hmong](#) | [Arabic](#) | [Armenian](#) | [Dari](#) | [Farsi](#) | [Hindi](#) | [Japanese](#) | [Korean](#) | [Portuguese](#) | [Punjabi](#) | [Russian](#) | [Vietnamese](#)
- Available on the EZIZ [LTCF Resources](#) page

Protect Against Flu, RSV, and COVID-19!

These diseases can be life-threatening
Patients and staff depend on each other to prevent severe illness, hospitalization, and death.

Protect Yourself and Your Community
Ask your doctor or care team for:

- ☐ Flu vaccine
- ☐ COVID-19 vaccine
- ☐ RSV vaccine
- ☐ Other recommended vaccines such as pneumococcal, shingles, and Tdap.

It's convenient and safe to receive all the vaccines you need on the same day!

Get vaccinated at:

IMM-1413 (7/24)

CDPH

Resources on EZIZ

Home
Vaccine Programs
Vaccine Management
Storage Units
Temperature Monitoring
Training & Webinars
Clinic Resources
Patient Resources

[Link to EZIZ Homepage](#)

Home

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

Contact VFC

Phone: (877) 243-8832
Hours:
Mon-Thurs, 9AM-4:30PM
Friday, 9AM-4PM
Send us an email
Fax: (877) 329-9832

- ▶ VFC Field Representatives
- ▶ Find VFC providers
- ▶ Sign up for EZIZ emails
- ▶ Frequently Asked Questions

California's Vaccine Programs

VFC
California Vaccines for Children Program

VFA
California Vaccines for Adults Program

BAP
California Bridge Access Program

LHD 317
Local Health Department 317 Program

Ordering & Vaccine Management

- MyCAvax (VFC, VFA, BAP, and 317)
- MyVFCvaccines (read-only)

Storage Requirements

- Vaccine Storage Units
- Digital Data Loggers

Alerts!

2024-25 COVID Vaccine

- COVID-19 Vaccine Timing Guide (8/30/24)
- Calendario de la Vacuna COVID-19 (9/10/24)
- COVID-19 Vaccine Product Guide (9/9/24)
- More Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturing Info

VFC vaccine ordering and management is now live at myCAvax!

Learn more about myCAvax move, recorded trainings and FAQs!

Holiday Ordering and Distribution for SGF

- September/October Calendar

VFC Memos

Vaccine Order Status

From CDPH

VFC Program Letters

- VFC 2024-2025 Flu Vaccine Ordering Information September 6
- myCAvax is Now the VFC Vaccine Management System June 14
- Clinical Letter for Penbraya (MenABCWY vaccine) May 16
- VFC is Moving to a New Vaccine Management System – myCAvax May 13

Hot Topics

CDPH Immunization Updates for Providers

- AIM Champion Awards
- S&H Job Aids for VFC, VFA, LHD 317 and SGF programs
- Reporting & Return of Nonviable Vaccines
- Reporting Excursions & Manufacturer Contacts
- COVID-19 Vaccine Resources
- VFC and Birthing Hospitals

Popular Resources

Protect Your Patients Against RSV!

- ▶ RSV Immunization FAQs
- ▶ Resources for Providers and Patients

Vaccine Resources

- ▶ Vaccine Fact Sheets
- ▶ Flu
- ▶ Measles
- ▶ Mpox
- ▶ Pertussis
- ▶ Schedules & Recommendations
- ▶ For Pharmacies

CDPH Applications

- ▶ myCAvax (ordering and management)
- ▶ MyVFCvaccines (read-only)
- ▶ My Turn (COVID/Flu Vaccine Administration System)
- ▶ CAIR (California Immunization Registry)
- ▶ My DVR (Digital Vaccine Records)
- ▶ CAIR-ME (Medical Exemptions from Immunizations for School and Child Care)

Updated
10.31.24

Provider FAQs

COVID-19 Vaccine and Therapeutics FAQs v.149_10.31.2024 1

COVID-19 Vaccine and Therapeutics FAQs

For providers administering COVID-19 vaccine and treating COVID-19.
Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

New and Updated FAQs	2
COVID-19 Vaccine Access	2
California Bridge Access Program (BAP)	4
Vaccines For Children (VFC) Program	6
Vaccine Administration	6
Vaccine Storage & Handling	10
Reporting	11
COVID-19 Therapeutics	13
Support & Resources	14



Q: Are there recommendations for a second dose of 2024 – 2025 COVID-19 vaccine?

A: On October 23, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended a second dose of the 2024 – 2025 COVID-19 vaccine 6 months after the first dose to people:

- 65 years and older
- 6 months – 64 years who are moderately or severely immunocompromised
 - additional doses (i.e., 3 or more) of 2024 – 2025 COVID-19 vaccine may be given to immunocompromised people 6 months – 64 years under [shared clinical decision making](#)

Please note the **minimum interval between COVID-19 vaccine doses is 2 months**. Refer to the following CDC resources for more information: [ACIP Recommendations](#), and [Clinical Guidance for COVID-19 Vaccination](#).



Q: Where can providers find information on COVID-19 treatment?

A: Information on COVID-19 treatment including who qualifies, treatment options, patient assistance programs, and related resources can be found on the [CDC COVID-19 Treatment Clinical Care for Outpatients page](#).

[Link to COVID-19 Provider FAQs](#)

COVID-19 Vaccine Product Guide 2024 – 2025

COVID-19 Vaccine Product Guide

Check vaccine labels and FDA materials before use to avoid mix-ups.
[Package inserts](#) and [EUA fact sheets](#) supersede info on vials and carton.

	Pfizer			
	Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Comirnaty 12+ years	Comirnaty 12+ years
			Single-Dose Vial 2024-25 Formula image not available	
	2024-25 Formula	2024-25 Formula		2024-25 Formula
Packaging	Yellow Cap	Blue Cap		Pre-Filled Syringe
Doses Per Vial	3 doses	1 dose	1 dose	1 dose/syringe
Carton Size	30 doses	10 doses	10 doses	10 doses
NDC-Unit of Sale (carton)	59267-4426-02	59267-4438-02	00069-2403-10	00069-2432-10
NDC-Unit of Use (vial/syringe)	59267-4426-01	59267-4438-01	00069-2403-01	00069-2432-01
CVX Code	308	310	309	309
CPT Code	91318	91319	91320	91320
Program Availability	VFC	VFC	Not available	VFC, CA BAP
Min. Standard Order*	30 doses	10 doses	N/A	10 doses
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.				
Shipping	Ships from manufacturer with dry ice between -90°C and -60°C (-130°F to -76°F)			2° to 8°C (36°F to 46°F)
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)			
Thermal Shipper				
Freezer				
Refrigerator	Up to 10 weeks at 2°C to 8°C (36°F to 46°F). Do not refreeze. Write the use-by date on carton—not to exceed expiration.			Until expiration at 2°C to 8°C
Expiration Date	Check the date on the product/carton, or for thawed products refer to the written use-by date.			Check label.
Administration				
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute	N/A
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time	Carton/Vial: Up to 2 hours at 2° to 8°C (36°F to 46°F) (Do not refreeze)			N/A
Room Temp Thaw Time	Vial: 30 minutes at up to 25°C (77°F) (Do not refreeze)			N/A
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)			
Storage Limits After Puncture (Multi-dose vials): Record puncture and use-by time on vial label.				
Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A	Use immediately after removing cap, within 4 hours.

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch IMM-1399 (9/24/24) Page 1 of 3

COVID-19 Vaccine Product Guide

Check vaccine labels and FDA materials before use to avoid mix-ups.
[Package inserts](#) and [EUA fact sheets](#) supersede info on vials and carton.

	Moderna		Novavax
	Pediatric 6 months–11 years	Spikevax 12+ years	Adol/Adult 12+ years
	2024-25 Product	2024-25 Product	2024-25 Formula image not available
Packaging	Pre-Filled Syringe	Pre-Filled Syringe	Pre-Filled Syringe
Doses Per Vial	1 dose/syringe	1 dose/syringe	1 dose/syringe
Carton Size	10 doses	10 doses	10 doses
NDC-Unit of Sale (carton)	80777-0291-80, Blister-sealed: 80777-0291-81	80777-0110-96, Blister-sealed: 80777-0110-93	80631-0107-10
NDC-Unit of Use (vial/syringe)	80777-0291-09	80777-0110-01	80631-0107-01
CVX Code	311	312	313
CPT Code	91321	91322	91304
Program Availability	VFC	VFC, CA BAP	VFC, CA BAP
Min. Standard Order*	10 doses	10 doses	10 doses
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.			
Shipping	Ships frozen between -50°C and -15°C (-58°F and 5°F)		2° to 8°C (36° to 46°F)
ULT			
Thermal Shipper			
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)		
Refrigerator	Up to 60 days (not to exceed expiration date) at 2–8°C (36–46°F)		Until expiration at 2–8°C (36–46°F)
Expiration Date	Check Moderna product website or QR code.		Check product website.
Administration			
Diluent	N/A		N/A
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50 mcg	0.5 mL 5 mcg
Refrigerator Thaw Time	Syringe: 1 hour Carton: 2.5 hours		N/A
Room Temp Thaw Time	Syringe: 45 minutes, Carton: 2 hours and 15 minutes		N/A
Total Room Temp Time	Store up to 12 hours at 8°C to 25°C (46°F to 77°F)		N/A
Storage Limits After Puncture			
Use-By Limit	N/A. Discard after single use.		N/A. Discard after single use.

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch IMM-1399 (9/24/24) Page 2 of 3

COVID-19 Vaccine Product Guide

Do Not Use Deauthorized Products:
 Use only COVID-19 vaccine products updated for 2024-25.

Pfizer		
Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Adol/Adult (Comirnaty) 12+ years
2021 Monovalent	2021 Monovalent	2021 Monovalent
Bivalent	Bivalent	Bivalent
2023-24	2023-24	2023-24 single-dose vial
		2023-24 syringe
Moderna		
Infant/Toddler 6 months–5 years	6 months+ Pediatric 6–11 years	Pediatric 6 mos–11 yrs
2021 Monovalent	Bivalent	2021 Monovalent
Bivalent	2023-24 single-dose vial	2023-24 single-dose vial
		2023-24 syringe
Janssen (J&J)		
Adult 18+ years		
2021 Monovalent		
Novavax		
Primary 12+ yrs Booster 18+		
2022 Monovalent	2023-24 multi-dose vial	

California Department of Public Health, Immunization Branch IMM-1399 (9/24/24) Page 3 of 3

COVID-19 Vaccine Product Guide 2024 - 2025

COVID-19 Vaccine Timing 2024-25 –Routine Schedule				
For online version and details view Interim Clinical Considerations for Use of COVID-19 Vaccines . Schedule is subject to change.				
Age*	Vaccine	If unvaccinated:		If had any prior doses, give 2024-25 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose	3–8 weeks**	2nd Dose ≥8 weeks 3rd Dose
	Moderna–Pediatric*	1st Dose	4–8 weeks**	2nd Dose
5–11 years	Moderna–Pediatric*	1 Dose		If 1 or more prior doses (of any of the brands), then†: ≥2 months‡ 2024-25 Moderna/Pfizer/Novavax
	Pfizer–Pediatric	1 Dose		
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose		If 1 or more prior doses (of any of the brands), then†: Ages 12–64 years: ≥2 months‡ 2024-25 Moderna/Pfizer/Novavax Ages 65+ years: ≥2 months‡ 1 6 months§ 2
	Moderna–Adol/Adult (Spikevax)	1 Dose		
	Novavax	1st Dose	3–8 weeks**	2nd Dose

* See [CDC recommendations](#) for children transitioning from a younger to older age group
† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.
** An 8-week interval may be preferable for some people, especially for males 12–39 years.
‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).
§ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.
§ Minimum interval 2 months.

COVID-19 Vaccine Timing 2024-25 if Moderately/Severely Immunocompromised				
Age	Vaccine	If unvaccinated:		If had any prior doses give 2024-25 doses:
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3 weeks	2nd Dose ≥8 weeks 3rd Dose 6 months§ Additional Dose(s)*
	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose ≥4 weeks 3rd Dose 6 months§ Additional Dose(s)*
5–11 years	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose ≥4 weeks 3rd Dose 6 months§ Additional Dose(s)*
	Pfizer–Pediatric	1st Dose	3 weeks	2nd Dose ≥4 weeks 3rd Dose 6 months§ Additional Dose(s)*
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose	3 weeks	2nd Dose ≥4 weeks 3rd Dose 6 months§ Additional Dose(s)*
	Moderna–Adol/Adult (Spikevax)	1st Dose	4 weeks	2nd Dose ≥4 weeks 3rd Dose 6 months§ Additional Dose(s)*
	Novavax	1st Dose	3 weeks	2nd Dose

* Further doses may be given under shared clinical decision-making at a minimum interval of 2 months. See [Table 2](#) for vial and dosage.
** Ages 5–11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax.
§ Minimum interval 2 months.

Updated COVID-19 Vaccine Timing Guide 10.28.24

Vaccine Support

Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.



Need help? View our job aids in the [Knowledge Center](#), or [contact us](#).



COVID-19 Therapeutics Resources

Type of Support

Description

Updated 7.8.24



Clinical Guidance

For general Therapeutics questions, please email: cdphtherapeutics@cdph.ca.gov



General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[Finding COVID-19 Treatments](#) (questions and answers for the public on finding COVID-19 treatments)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more for providers)


[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (find COVID-19 medications near you)
- [Information Page for Test-to-Treat](#) Program (hhs.gov)



[Archive LHD Therapeutics SharePoint](#)

For access to previously recorded LHD webinars and slides contact: rphoadmin@cdph.ca.gov

For Information on how to registers for HPOP reporting information, use link below.

- [CDPH Therapeutics HPoP Account Verification & Reporting](#) information



Questions

For general CDPH Therapeutics questions, please email cdphtherapeutics@cdph.ca.gov

For ordering, program inquiries, signing up new HPOP Accounts: please e-mail cdphtherapeutics@cdph.ca.gov

CDPH Provider Webinars and Trainings

Week of November 4, 2024


	Monday 11/4	Tuesday 11/5	Wednesday 11/6	Thursday 11/7	Friday 11/8
Live Webinars and Training	No Events Scheduled at this time				
View On Demand	<ul style="list-style-type: none">• CDPH Immunization Branch Archived Provider Webinars and Slides• AIM Vaccine Confidence Toolkit Webinar Series		<ul style="list-style-type: none">• Introduction to My Turn Onboarding (v. 1/4/22)• Latest Features in My Turn (Requires myCAvax Login)• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)		
Help	Help Desk CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov Mpox: Email: stdcb@cdph.ca.gov			Immunization Resources California's General Immunization Resources (eziz.org) RSV Immunization Resources Flu Vaccination Resources COVID-19 Vaccination Resources COVID-19 Treatments Mpox Vaccination Resources	

CDPH Provider Webinars and Trainings


Week of November 11, 2024

	Monday 11/11	Tuesday 11/12	Wednesday 11/13	Thursday 11/14	Friday 11/15
Live Webinars and Training	<i>Veteran's Day Holiday</i>	<u>Virtual Grand Rounds: From Avian Flu to COVID-19 – How the “One Health” Approach Improves Human, Animal and Environmental Health</u> 12:00 pm – 1:00 pm			<u>CDPH Immunization Updates for Providers</u> 9:00 am – 10:30 am
View On Demand	<ul style="list-style-type: none">• CDPH Immunization Branch Archived Provider Webinars and Slides• AIM Vaccine Confidence Toolkit Webinar Series		<ul style="list-style-type: none">• Introduction to My Turn Onboarding (v. 1/4/22)• Latest Features in My Turn (Requires myCAvax Login)• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)		
Help	Help Desk CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm <i>Email:</i> providercallcenter@cdph.ca.gov My Turn: <i>Help Desk Email:</i> myturn.clinic.hd@cdph.ca.gov <i>Onboarding Email:</i> myturnonboarding@cdph.ca.gov myCAvax: <i>Help Desk Email:</i> mycavax.hd@cdph.ca.gov Mpox: <i>Email:</i> stdcb@cdph.ca.gov			Immunization Resources California's General Immunization Resources (eziz.org) RSV Immunization Resources Flu Vaccination Resources COVID-19 Vaccination Resources COVID-19 Treatments Mpox Vaccination Resources	

Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



Thank you for attending!



**Immunization
Branch**

Next CDPH Immunization Updates for Providers
Friday, November 15, 2024

[CDPH Immunization Updates for Providers
Registration Link](#)